Verily

News
Card image cap

Verily taps Oncimmune tech for 'long COVID' study

Alphabet's Verily Life Science has contracted UK biotech Oncimmune to investigate autoantibodies in people who have developed long-lasting symptoms after COVID-19 infection, a condition kno